Device Trial Radar · NCT06672159
Initial Double Sequential External Defibrillation in Out of Hospital Cardiac Arrest
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
356
Planned (sponsor's estimate)
Start
Apr 28, 2025
Primary completion
Jun 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- St. Olavs HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Norwegian Air Ambulance Foundation
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double Sequential External Defibrillation (DSED) represents an alternative treatment of refractory ventricular fibrillation (rVF) in out-of-hospital cardiac arrest (OHCA). The procedure consists of two defibrillators that administer shocks at the same time. Currently, the procedure is not initiated before at least three failed attempts with one defibrillator. This can delay the potential benefits of establishing DSED earlier in the treatment. Studies have shown that early defibrillation is crucial for survival in OHCA patients, and in 2022, a clinical trial showed that survival in patients treated with DSED was higher compared to standard treatment. The effect of initiating OHCA treatment is unknown. The DUALDEFIB trial seeks to investigate if treating OHCA patients with DSED as an initial treatment will increase survival and provide improved neurological outcome.
Conditions
- Cardiac Arrest
- Out-Of-Hospital Cardiac Arrest
- Ventricular Fibrillation
Interventions
Two defibrillatorsDevice
DSED procedure consists of pads placed in anterior-lateral position, and in anterior-posterior position. Defibrillations will be given in rapid sequence, less than a second apart. All other aspects of resuscitation in accordance to existing guidelines.
One defibrillatorDevice
Standard OHCA treatment according to existing guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients that survive to hospital admission.Time frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St Olavs Hospital
Trondheim, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.